Recent Press Releases

ImmusanT Raises $12 Million in Series B Financing

ImmusanT Raises $12 Million in Series B Financing Funding Will Enable Phase 2 Advancement of ImmusanT's Immunotherapy for Celiac Disease December 22, 2014 09:00 AM Eastern Standard Time...

N30 Pharmaceuticals Appoints Jon Congleton as President and CEO

N30 Pharmaceuticals Appoints Jon Congleton as President and CEO BOULDER, Colo., Dec. 22, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma"), a clinical-stage, biopharmaceutical...

BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza

RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) a pharmaceutical company focused on the development and commercialization of treatments...

FDA approves new antibacterial drug Zerbaxa

The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and...

CUBIST ANNOUNCES FDA APPROVAL OF NEW ANTIBIOTIC ZERBAXA™ (CEFTOLOZANE/TAZOBACTAM) FOR COMPLICATED URINARY TRACT AND COMPLICATED INTRA-ABDOMINAL INFECTIONS

ZERBAXA addresses certain serious and resistant Gram-negative bacteria First new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Lexington, Mass. – Cubist...

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies

MacroGenics licenses MGD011 (CD19 x CD3 DART(R)) to Janssen $50 million upfront license fee paid to MacroGenics, and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc....

Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting

Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – Results Presented at American Association for the Study of Liver Diseases...

Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422

- A six-week dual NS5A - Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study") - ACH-3422...

Bina Technologies is acquired by Roche.

REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.

FDA approves Viekira Pak to treat hepatitis C

The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus...

FDA approves Lynparza to treat advanced ovarian cancer

The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as...

The Fonds de solidarité FTQ Invests $4 Million in Zymeworks Inc. in Support of Québec's Health Sciences Sector

MONTRÉAL, Canada & VANCOUVER, Canada--The Fonds de solidarité FTQ, a Québec-based development capital fund, today announced an investment of $4 million in common shares of...

ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial

WALTHAM, Mass.-- ImmunoGen, Inc. (IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has...

Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures.

Acesion Pharma, a Danish biotech company developing novel therapeutic treatments for atrial fibrillation (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity...

Lundbeck discontinues further development of desmoteplase; 2014 profit guidance range narrowed

Valby, Denmark, 17 December 2014 - H. Lundbeck A/S (Lundbeck) today announced that following the evaluation of the entire available data package including results from DIAS-4 on the investigational...

BerGenBio completes NOK90 million fundraising

Bergen, Norway, December 15, 2014 – BerGenBio AS, a biopharmaceutical company focused on developing innovative drugs for aggressive drug resistant cancers, today announces that it has raised...

Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases,...

Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology

INDIANAPOLIS and LYON, France, Dec. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing...

Lion Biotechnologies, Inc. Names Elma Hawkins President, CEO, And Director

LOS ANGELES, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today...